Pfizer partnership uses RWD to advance precision oncology
The partnership will see the companies using data from clinical practices participating in the American Society of Clinical Oncology’s (ASCO) CancerLinQ, which is considered to be one of the most comprehensive real world data (RWD) sets available from Concerto.
The collaboration aims to accelerate actionable patient insights for Pfizer’s precision oncology work on investigational and commercialized therapeutics for the treatment of solid tumors and hematologic malignancies.
Jeff Elton, CEO of Concerto HealthAI told us, “We are building the platform and capability to use data science and real world data to inform synergistic combinations, alternative treatment strategies, and the most efficient clinical research approaches – all in service of advancing these new medicines to patients more rapidly and confidently.”
Per the agreement, the two companies will design and conduct a synthetic control arm and prospective RWD outcomes study for therapeutics both pre- and post- approval using Concerto’s eurekaHealth platform.
The AI platform from Concerto combines data products with a user’s first-party data to accelerate and advance study designs. The design project between the two companies will build on work already ongoing by CincerLinQ and Concerto HealthAI.
Elton further explained the platform as an environment that supports an array of Concerto HealthAI data products, which can be combined with its partner’s first-party data to enable study execution informed by real world evidence.
“The collaboration confirms that ‘precision evidence’ is a key enabler of ‘precision oncology’ – we are both bringing the best of our respective organizations to bear, compelled by a single mission to advance treatment options, with the strongest form of evidence, as efficiently and rapidly as possible – all in service of our commitment to bring better treatment options to patients faster,” Elton added.
The call for increased use of RWD and RWE from the US Food and Drug Administration (FDA) through the 21st Century Cures Act has increased the size of RWD data sets, sparking new partnerships across the industry, according to Elton.
Bristol-Myers Squibb also recently tapped Concerto HealthAI to bolster its precision treatment options through RWD and deploy a RWE-centric clinical development model.
